Suresh Ramalingam

Suresh Ramalingam at Emory has led landmark lung cancer trials, including FLAURA establishing osimertinib as first-line standard of care for EGFR-mutant NSCLC — demonstrating superior progression-free and overall survival compared to first-generation EGFR inhibitors. He also led LAURA establishing osimertinib after concurrent chemoradiation in stage III EGFR-mutant NSCLC and contributed to ADAURA establishing adjuvant osimertinib. His contributions have defined the modern treatment of EGFR-mutant lung cancer.